Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 925-384-5 | CAS number: 90639-98-8
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
There are no experimental and/or literature specific data on L-CARNITINEAMIDE D-CAMPHORATED.
The analysis was carried out by calculation tools, but results were not exhaustive, since it is a salt, public programs are outside the application field and can not be used. Therefore it has been evaluated the comparison with the base (Camphor; CAS: 76 -22 -2; EC: 200 -945 -0) and the counter-ion(Levocarnitine; CAS: 541 -15 -1; EC: 208 -768 -0)of the substance, because the metabolism pathway of the substance is dissociate to its base and counter-ion, Camphor and Levocarnitine, and Camphor undergos to further transformation to Camphoric acid by ossidative metabolism.
Data available on Camphor [*-15, 16, 17] reported slight adverse effects at high dose administrated, while data available on Levocarnitine [*21, 22] do not report mutagenic affects.
In both cases substances are consider as NON mutagent agents and the L-Carnitineamide D-Champorated is not expected to be mutagen, too.
Any details about data available are reported in the report attached at the point 13: Assessment Report.
Reference
[*]Secondary source: Hazardous Substances Data Bank – HSDB - U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894, National Institutes of Health, Department of Health & Human Services
[15] National Poisons Information Service Center, United Kingdom; Poisons Information Monograph: Camphor. (March 1996). Available from, as of February 6, 2004:http://www.intox.org/databank/documents/pharm/camphor/ukpid19.htm **PEER REVIEWED**
[16] Goel HC et al; Mutat Res 224 (2): 157-60 (1989) **PEER REVIEWED**
[17] Gomes-Carneiro MR et al; Mutat Res 416 (1-2): 129-36 (1998) **PEER REVIEWED**
[21] Thorne Research, Inc.; Monograph on Acetyl-L-Carnitine; Alternative Medicine Review 4(6) p.439 (1999). Available from, as of February 26, 2008: http://www.thorne.com/altmedrev/.fulltext/4/6/438.pdf **PEER REVIEWED**
[22] Thorne Research, Inc.; Monograph on L-Carnitine; Alternative Medicine Review 10(1) p.47 (2005). Available from, as of February 25, 2008: http://www.thorne.com/altmedrev/.fulltext/10/1/42.pdf **PEER REVIEWED**
Short description of key information:
Non mutagen
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
Based on read across evaluation, the L-Carnitineanide D-Camphorated is not expected to be mutagen.
According to the Regulation EC 1272/2008 (CLP) L-Carnitineamide D-Camphorated is classified as non mutagen.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
